Carbinoxamine Maleate
The maleate salt form of carbinoxamine provides first-generation antihistamine activity, reducing symptoms of allergic rhinitis, urticaria, and other allergic conditions. Like the parent compound, it crosses the blood-brain barrier and may cause drowsiness. It is commonly found in liquid formulations intended for pediatric use.
Khối lượng phân tử
406,9000 g/mol
TPSA
100,00 Ų
Cơ chế tác dụng
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Cấu trúc 2D
Cite this structure
Embed this structure
SMILES
CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O
InChI
InChI=1S/C16H19ClN2O.C4H4O4/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-10,16H,11-12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
Molecular Formula
C20H23ClN2O5
HBD / HBA
2 / 7
Liên kết có thể quay
8
Nguyên tử nặng
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
The maleate salt form of carbinoxamine provides first-generation antihistamine activity, reducing symptoms of allergic rhinitis, urticaria, and other allergic conditions. Like the parent compound, it crosses the blood-brain barrier and may cause drowsiness. It is commonly found in liquid formulations intended for pediatric use.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Carbinoxamine Maleate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200974. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5282409. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="carbinoxamine-maleate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/carbinoxamine-maleate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/carbinoxamine-maleate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/carbinoxamine-maleate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="carbinoxamine-maleate"></drugfyi-drug>